# Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED)

> **NCT00694083** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 13 (actual)

## Conditions studied

- Neoplasm

## Interventions

- **DRUG:** Ridaforolimus

## Key facts

- **NCT ID:** NCT00694083
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06-10
- **Primary completion:** 2009-09-06
- **Final completion:** 2009-09-06
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2024-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00694083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00694083, "Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00694083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*